Similarly, in the combined case-control and cohort study by Wium-Andersen and colleagues, 33 low doses of metformin, DPP-4 inhibitors, GLP-1 analogs, and SGLT2 inhibitors were associated with a lower risk of depression in patients with diabetes compared to non users, with the lowest risk for sodium-glucose transport protein 2 inhibitor users
Moreover, among these individuals, approximately 41% have MASH and around 15% present with advanced fibrosis (stage F3) [7]
Cloudy or particulate solutions should not be used
Glutathione still works, but timing matters
Comments (5) Effective July 1, health insurer Cigna (CI) will no longer cover GLP-1 weight-loss drugs such as Novo Nordisks (NVO) Wegovy and Eli Lillys (LLY) Zepbound in its employee health plan, Reuters reported, citing internal company communications
& Englund, M